Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OrganoClick ABFRA:0CF -18.07%25 Equity-to-Asset is 0.10 as of Mar. 2026, which is 68% below its 10-year median of 0.31. GuruFocus rates FRA:0CF with a GF Score™ of 25/100 and a GF Value™ of €0.13. The stock has 4 warning signs investors should review. Among 1,614 Chemicals companies, OrganoClick AB ranks worse than 96.65% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. OrganoClick AB's Total Stockholders Equity for the quarter that ended in Mar. 2026 was €1.30 Mil. OrganoClick AB's Total Assets for the quarter that ended in Mar. 2026 was €13.71 Mil.
Therefore, OrganoClick AB's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.10.
The historical rank and industry rank for OrganoClick AB's Equity-to-Asset or its related term are showing as below:
FRA:0CF'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.06 Med: 0.31 Max: 0.58
Current: 0.1
During the past 13 years, the highest Equity to Asset Ratio of OrganoClick AB was 0.58. The lowest was 0.06. And the median was 0.31.
FRA:0CF's Equity-to-Asset is ranked worse than 96.65% of 1614
companies
in the Chemicals industry
Industry Median: 0.6
vs FRA:0CF: 0.10
OrganoClick AB (FRA:0CF) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
OrganoClick AB Equity-to-Asset Related Terms
OrganoClick AB Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for OrganoClick AB's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:0CF vs LIN, SHW, ECL: Equity-to-Asset Comparison
For the Specialty Chemicals subindustry, OrganoClick AB's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OrganoClick AB Equity-to-Asset vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, OrganoClick AB's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where OrganoClick AB's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
OrganoClick AB's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OrganoClick AB (FRA:0CF) has a Equity-to-Asset of 0.10 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on OrganoClick AB and its competitors. This is 68% below median its historical median of 0.31. Over the past decade, OrganoClick AB's Equity-to-Asset has ranged from 0.06 to 0.58. According to the industry distribution chart, OrganoClick AB ranks #1560 out of 1614 companies in the Chemicals industry, placing it in the top 96.7%.
Is OrganoClick AB's Equity-to-Asset too high?
OrganoClick AB's current Equity-to-Asset of 0.10 is 68% below median its 10-year median of 0.31. Over the past 10 years, this metric has ranged from a low of 0.06 to a high of 0.58. The Chemicals industry median Equity-to-Asset is 0.60. OrganoClick AB's value of 0.10 is 83.3% below this industry median. Based on the distribution chart, OrganoClick AB ranks #1560 out of 1614 companies in the Chemicals industry, which is in the bottom quartile relative to peers. Overall, OrganoClick AB has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does OrganoClick AB's Equity-to-Asset compare to LIN and SHW?
According to the Chemicals industry distribution chart, OrganoClick AB ranks #1560 out of 1614 companies for Equity-to-Asset. This places OrganoClick AB in the lower half of its industry. The industry median Equity-to-Asset is 0.60. OrganoClick AB's value of 0.10 is 83.3% below this benchmark. Historically, OrganoClick AB's own Equity-to-Asset has ranged from 0.06 to 0.58 over the past decade. While the company's 10-year median is 0.31 vs. the industry median of 0.60, OrganoClick AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Chemicals company?
The median Equity-to-Asset among Chemicals companies is 0.60, based on 1,614 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OrganoClick AB's current Equity-to-Asset of 0.10 is 83.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on OrganoClick AB and its competitors. For the Chemicals industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OrganoClick AB's current Equity-to-Asset is 0.10, which is 68% below median its own 10-year median of 0.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OrganoClick AB stock overvalued right now?
OrganoClick AB (FRA:0CF) has a current Equity-to-Asset of 0.10. The stock's GF Value™ is €0.13, compared to a current price of €0.03 — trading 79.1% below its estimated fair value. The current Equity-to-Asset is 0.10, which is 68% below median its 10-year median of 0.31 and 83.3% below the Chemicals industry median of 0.60. OrganoClick AB's overall GF Score™ is 25/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For OrganoClick AB (FRA:0CF), the current Equity-to-Asset is 0.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OrganoClick AB (FRA:0CF) Overvalued in 2026?
Based on GuruFocus' analysis, OrganoClick AB stock appears to be undervalued.
The current stock price of €0.03 is trading 79.1% below its estimated GF Value™ of €0.13.
Key valuation signals for FRA:0CF:
Equity-to-Asset: 0.10 (68% below median its 10-year median of 0.31)
GF Value™: €0.13 vs. price of €0.03 (79.1% below fair value)
Industry Position: 83.3% below the Chemicals median (#1560 of 1614)
No single metric tells the full story. See the FRA:0CF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OrganoClick AB is involved in the chemicals industry. Its product portfolio includes green chemical technologies for creating water repellency, biobased binders for increasing the mechanical strength, and wood treatment products for resistance to fungal degradation and resistance to fire. It operates in four business areas Functional Wood, Green coatings & maintenance products, Nonwoven & technical textile, and Other. The group has a single operating segment.
25GF Score
Get the complete analysis for FRA:0CF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:0CF has been successfully added to your 
